Skip to main content

A new 68Ga-labeled somatostatin analog containing two iodo-amino acids for dual somatostatin receptor subtype 2 and 5 targeting



Somatostatin receptor (SST) targeting, specifically of the subtype 2 (SST2), with radiolabeled somatostatin analogs, is established for imaging and treatment of neuroendocrine tumors. Owing to the concomitant and heterogeneous expression of several subtypes on the same tumor, analogs targeting more subtypes than SST2 potentially target a broader spectrum of tumors and/or increase the uptake of a given tumor. The analog ST8950 ((4-amino-3-iodo)-d-Phe-c[Cys-(3-iodo)-Tyr-d-Trp-Lys-Val-Cys]-Thr-NH2), bearing 2 iodo-amino acids, exhibits sub-nanomolar affinity to SST2 and SST5. We report herein the development and preclinical evaluation of DOTA-ST8950 labeled with 68Ga, for imaging SST2- and SST5-expressing tumors. Comparative in vitro and in vivo studies were performed with the de-iodinated DOTA-ST8951 ((4-amino)-d-Phe-c[Cys-Tyr-d-Trp-Lys-Val-Cys]-Thr-NH2) and with the reference compounds DOTA-TATE (SST2 selective) and DOTA-NOC (for SST2 and SST5).


Compared with natGa-DOTA-NOC, natGa-DOTA-ST8950 exhibited higher affinity to SST2 and SST5 (IC50 (95%CI), nM = 0.32 (0.20–0.50) and 1.9 (1.1–3.1) vs 0.70 (0.50-0.96) and 3.4 (1.8-6.2), respectively), while natGa-DOTA-ST8951 lost affinity for both subtypes. natGa-DOTA-ST8950 had the same potency for inducing SST2-mediated cAMP accumulation as natGa-DOTA-TATE and slightly better than natGa-DOTA-NOC (EC50, nM = 0.46 (0.23–0.92) vs 0.47 (0.15–1.5) vs 0.59 (0.18–1.9), respectively). [67Ga]Ga-DOTA-ST8950 had a similar internalization rate as [67Ga]Ga-DOTA-NOC in SST2-expressing cells (12.4 ± 1.6% vs 16.6 ± 2.2%, at 4 h, p = 0.0586). In vivo, [68Ga]Ga-DOTA-ST8950 showed high and specific accumulation in SST2- and SST5-expressing tumors, comparable with [68Ga]Ga-DOTA-NOC (26 ± 8 vs 30 ± 8 %IA/g, p = 0.4630 for SST2 and 15 ± 6 vs 12 ± 5 %IA/g, p = 0.3282, for SST5, 1 h p.i.) and accumulation in the SST-positive tissues, the kidneys and the liver. PET/CT images of [68Ga]Ga-DOTA-ST8950, performed in a dual HEK-SST2 and HEK-SST5 tumor xenografted model, clearly visualized both tumors and illustrated high tumor-to-background contrast.


[68Ga]Ga-DOTA-ST8950 reveals its potential for PET imaging SST2- and SST5-expressing tumors. It compares favorably with the clinically used [68Ga]Ga-DOTA-NOC in terms of tumor uptake; however, its uptake in the liver remains a challenge for clinical translation. In addition, this study reveals the essential role of the iodo-substitutions in positions 1 and 3 of [68Ga]Ga-DOTA-ST8950 for maintaining affinity to SST2 and SST5, as the de-iodinated [68Ga]Ga-DOTA-ST8951 lost affinity for both receptor subtypes.


Nuclear imaging of somatostatin receptor (SST)-expressing tumors is established for the detection of neuroendocrine tumors (NETs) and their metastases. SST scintigraphy, using [111In][In-diethylenetriaminepentaacetic acid0]-octreotide ([111In]In-DTPA0-octreotide, Octreoscan®), has covered this medical need since the 1990s. Nowadays, positron emission tomography (PET) with improved octreotide-based analogs labeled with 68Ga represents the state of the art. The most widely used analogs consist of the [68Ga][Ga-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid0,Tyr3]-octreotide ([68Ga]Ga-DOTA-TOC, SOMAKIT TOC®) with a high affinity for SST2 and a weaker affinity for SST5 (IC50 = 2.5 ± 0.5 and 73 ± 21 nM, respectively) and the high affinity SST2-selective [68Ga][Ga-DOTA0,Tyr3,Thr8]-octreotate ([68Ga]Ga-DOTA-TATE, NETSPOT®) with an IC50 of 0.20 ± 0.04 nM [1].

Although the majority of NETs expresses SST2, a low and heterogeneous expression has been reported in approximately 20–30% of cases [2,3,4,5]. This is associated with an inherent worse disease prognosis, a lower sensitivity in imaging and an ineffective therapy with SST2-specific analogs due to inadequate tumor targeting [6]. Among the five SST subtypes (SST1-SST5), SST5 is concomitantly expressed at high density in 70–100% of gastroenteropancreatic neuroendocrine tumors (GEP-NETs), breast cancer and in growth hormone (GH)-secreting pituitary adenomas [7,8,9].

The only clinically used analog for imaging of different SST subtypes is the octreotide-based [68Ga][Ga-DOTA0,1-Nal3]-octreotide ([68Ga]Ga-DOTA-NOC), with high affinity for SST2 and SST5 and lower affinity for SST3 [10,11,12]. The cyclohexapeptide pasireotide (Signifor®, formerly known as SOM230) [13, 14] is another analog with an affinity for SST2, SST3, and SST5 that have been evaluated preclinically with 68Ga ([68Ga]Ga-DOTA-SOM230 [15, 16] or [68Ga]Ga-DOTA-PA1 [17]). Other preclinical attempts for combined targeting of different subtypes involve 111In-labeled analogs of (a) NOC [18], (b) carbocyclic octapeptides based on the cyclic KE108 with a non-disulfide 8 member ring [19]; (c) 14mer and pseudo-14mer cyclic somatostatin-14 (SS-14) mimics, with ring-size of 12, 9, 8, and 6 amino acids [20, 21], and (d) somatostatin-28 (SS-28) modified at positions 8, 22, and 25 [22]. All the abovementioned radiotracers showed certain limitations, with [68Ga]Ga-DOTA-NOC being, so far, the only one used in the clinic.

We are interested in developing somatostatin analogs with high affinity to SST2 and SST5 for targeting a broader spectrum of tumors and/or increasing the tumor uptake, when both receptor subtypes are concomitantly present. A library of disulfide-bridged octapeptides based on RC-121 (d-Phe-c(Cys-Tyr-d-Trp-Lys-Val-Cys)-Thr-NH2) [23] that contains synthetic amino acids and modifications at positions 1, 3, and 8 was developed by Moore et al [24]. Out of this library, ST8950 (Fig. 1, peptide #9 in reference [24]) bearing the 2 iodo-amino acids 4-amino-3-iodo-phenylalanin in position 1 and 3-iodo-tyrosine in position 3 exhibited sub-nanomolar affinity to both SST2 and SST5 and showed to be as potent as the natural SS-14 in the inhibition of growth hormone and prolactin release. We previously reported that ST8950 (AP102 in references [25, 26]) has an intermediate agonistic potency between octreotide and pasireotide at SST2 and SST5 level [25] and reduces growth hormone secretion without causing hyperglycemia (a known undesirable effect of pasireotide) in a healthy rat model [26]. We aimed to develop and evaluate 68Ga-labeled ST8950 for PET imaging of SST2- and SST5-expressing tumors and we used DOTA as a chelator. Knowing that modifications such as chelator conjugation and (radio)metallation impact on affinity and whole-body distribution of radiolabeled somatostatin analogs [10, 27], with sometimes unexpected outcome, we decided to include in our study a second analog as an alternative. We chose the de-iodinated ST8951 (Fig. 1, peptide #2 in reference [24]) that exhibits also good affinity to SST2 and SST5 in an attempt to assess, additionally, the influence of the iodo-substitution on the Ga-DOTA conjugates.

Fig. 1

The structural formulae of the four DOTA-conjugated somatostatin analogs (DOTA-ST8950: DOTA-(4-amino-3-iodo)-d-Phe-c[Cys-(3-iodo)-Tyr-d-Trp-Lys-Val-Cys]-Thr-NH2, DOTA-ST8951: DOTA-(4-amino)-d-Phe-c[Cys-Tyr-d-Trp-Lys-Val-Cys]-Thr-NH2, DOTA-NOC: DOTA-d-Phe-c[Cys-1-NaI-d-Trp-Lys-Thr-Cys]Thr(ol) and DOTA-TATE: DOTA-d-Phe-c[Cys-Tyr-d-Trp-Lys-Thr-Cys]Thr)


(Radio)metallated peptide conjugates

DOTA-ST8950 and DOTA-ST8951 were custom-made by PolyPeptide (San Diego, USA). The reference conjugates DOTA-TATE and DOTA-NOC were synthesized following Fmoc-solid-phase peptide synthesis, purified by preparative reverse phase high-performance liquid chromatography (RP-HPLC) and characterized by electrospray ionization mass spectroscopy (ESI-MS). The structural formulae of all four conjugates are presented in Fig. 1.

The natGa complexes of the four conjugates were prepared using 2.5-fold excess of natGa(NO3)3 × 9H2O in ammonium acetate buffer, 0.2 M, pH 4 at 95 °C for 30 min. Free metal ions were eliminated via SepPak C-18 cartridge (Waters), pre-conditioned with methanol and water. The reaction mixture was loaded and the free natGa was eluted with water while the metallo-peptides were eluted with ethanol, evaporated to dryness, re-dissolved in water and lyophilized.

67Ga-labeled conjugates were prepared by reacting 6 nmol of the corresponding conjugate in 250 μL Na-acetate buffer (0.2 M, pH 4.1) with [67Ga]GaCl3 (30-50 MBq, Mallinckrodt) at 95 °C for 30 min. DOTA-ST8950 and DOTA-NOC were labeled with 68Ga in an automatic Modular-Lab Pharm Tracer module (Eckert & Ziegler). Briefly, the 68Ge/68Ga-generator (IGG100, Eckert & Ziegler) was eluted with 7 mL HCl 0.1 N and the eluate (~ 800 MBq) was loaded onto a cation exchange column (Strata-XC, Phenomenex). 68Ga3+ was eluted with 800 μL of acetone/HCl (97.6%/0.02 N) in a vial containing 2 mL Na-acetate buffer (0.2 M, pH 4.0) and 10 nmol of the conjugate. The stability of [68Ga]Ga-DOTA-ST8950 was evaluated for 1 h after production at room temperature (RT), without any formulation of the product.

The quality control and the stability study were performed by analytical RP-HPLC on Phenomenex Jupiter Proteo 90 Å C12 (250 × 4.6 mm) column (eluents: A = H2O (0.1%TFA), B = acetonitrile (0.1% TFA); gradient: 95–50% A in 15 min; flow rate: 1.5 mL/min). ESI-MS was carried out with ESI Bruker Esquire 3000 plus (Bruker Daltonics).

Cell lines, affinity studies, and functional assays

Human Embryonic Kidney (HEK293) cells (a kind gift from Dr. A. Mühlethaler-Mottet, Pediatric Hematology-Oncology Unit, Lausanne University Hospital, Switzerland) were stably transfected with plasmids encoding the human SST2 and SST5 (HEK-SST2 and HEK-SST5) and cultivated as previously described [25]. Non-transfected HEK cells were used as a negative control.

The binding affinities of natGa-DOTA-ST8950 and natGa-DOTA-ST8951, in comparison to natGa-DOTA-TATE and natGa-DOTA-NOC, were determined on HEK-SST2 and HEK-SST5 cells. SS-14, octreotide, and pasireotide were used as reference compounds. 125I-labeled SS-14 (81.4 TBq/mmol, Perkin Elmer) was used as a radioligand for the competition binding assays. Binding assays were performed as described previously [25].

cAMP accumulation experiments on HEK-SST2 and HEK-SST5 cells were performed with cAMP direct immunoassay kit (colorimetric, K371, BioVision) as described previously [25].

Log D measurement

Log D (pH = 7.4) was determined by the “shake-flask” method. To a pre-saturated mixture of 500 μL n-octanol and 500 μL of phosphate-buffered saline (PBS) at pH 7.4, 10 μL of 1 μM of 67Ga-labeled conjugates was added. The solutions were vortexed for 1 h to reach equilibrium and then centrifuged (3000 rpm) for 10 min. From each phase, 100 μL was removed and measured in a γ-counter. The partition coefficient was calculated as the average of the logarithmic values (n = 3) of the ratio between the radioactivity in the organic and the PBS phase.

In vitro characterization

For cell experiments, stably SST2- and SST5-expressing cells were seeded in 6-well plates (106 cells/well) and incubated overnight with Dulbecco’s modified Eagle’s medium (DMEM) with 1% fetal bovine serum (FBS, Biochrom GmbH, Merck Millipore) to obtain a good cell adherence. The plates were pre-treated with a solution of 10% poly-lysine to promote cell adherence.

Internalization assays

The cells were washed with PBS and incubated with fresh medium (DMEM with 1% FBS) for 1 h at 37 °C/5% CO2. [67Ga]Ga-DOTA-ST8950, [67Ga]Ga-DOTA-ST8951, [67Ga]Ga-DOTA-TATE, or [67Ga]Ga-DOTA-NOC (2.5 nM) were added to the medium, and the cells were incubated for 0.5, 1, 2, and 4 h at 37 °C/5% CO2 (in triplicates). The internalization process was stopped by removing the medium and washing the cells with ice-cold PBS, followed by 2 × 5 min treatment with ice-cold glycine solution (0.05 M, pH 2.8), to distinguish between cell surface-bound (acid releasable) and internalized (acid resistant) radio-conjugate. Finally, the cells were detached with 1 M NaOH at 37 °C. To determine non-specific uptake, selected wells were incubated with the radio-conjugate in the presence of 1000-fold excess of SS-14. Internalization and bound rate are expressed as a percentage of the applied radioactivity.

Off-rate experiments

HEK-SST2 cells were incubated with [67Ga]Ga-DOTA-ST8950, [67Ga]Ga-DOTA-TATE, or [67Ga]Ga-DOTA-NOC (2.5 nM) for 2 h. The medium was removed and the wells were washed with ice-cold PBS. The surface-bound radio-conjugate was removed with a glycine solution (pH 2.8) on ice, as described above. Cells were then incubated again at 37 °C with a fresh medium. At 10, 20, 30, 60, 120, and 240 min, the medium was removed for quantification of radioactivity and replaced with a fresh 37 °C medium. At the end of the experiment, the cells were detached with 1 M NaOH and collected for quantification of the radioactivity.

In vivo evaluation

The Veterinary Office (Department of Health) of the Cantonal Basel-Stadt approved the animal experiments (approval no. 2799) in accordance with the Swiss regulations for animal treatment. Female athymic Nude-Foxn1nu/Foxn1+ mice (Envigo, The Netherlands), 4–6 weeks old, were inoculated subcutaneously with 107 HEK-SST2 cells on the right shoulder and 107 HEK-SST5 cells on the left shoulder, suspended in 100 μL sterile PBS. The tumors were allowed to grow for 2–3 weeks until reach an average volume of 100 mm3, considering both tumor types. The average tumor mass was 0.22 g (0.14–0.31 g) for SST2 tumors and 0.13 g (range 0.08–0.21) for SST5 tumors. For the biodistribution (cohorts of n = 3–8 mice) and imaging studies, the mice were euthanized by keeping them in a CO2 chamber 2 min, followed by a slow increase of the concentration of CO2 gas. The mice with the largest tumors were used for PET imaging.

Biodistribution studies of [68Ga]Ga-DOTA-ST8950 and [68Ga]Ga-DOTA-NOC

Quantitative biodistribution studies were conducted with [68Ga]Ga-DOTA-ST8950 (100 μL/100 pmol/5 MBq) at 1 and 2 h p.i. Biodistribution of [68Ga]Ga-DOTA-NOC was assessed 1 h p.i. for comparison. The organs of interest were collected, rinsed, blotted, weighed, and counted in a γ-counter. The results are expressed as the percentage of injected activity per gram (%IA/g) obtained by extrapolation from counts of an aliquot taken from the injected solution as a standard. The specificity of uptake of [68Ga]Ga-DOTA-ST8950 was assessed 1 h p.i in HEK-SST-negative xenografted mice.

PET/CT imaging of [68Ga]Ga-DOTA-ST8950 and [68Ga]Ga-DOTA-NOC

[68Ga]Ga-DOTA-ST8950 or [68Ga]Ga-DOTA-NOC (100 μL/100 pmol/5 MBq) was administered to mice bearing dual HEK-SST2 and HEK-SST5 tumors. One-hour p.i. the mice were euthanized, and the bladder was emptied by gently pressing with hands around the bladder area. The excess urine was soaked by cotton, followed by repetitive cleaning of the area with ethanol. The mice were scanned for 60 min using a human PET/CT scanner (Discovery STE, GE Medical Systems). A scout scan (180°, 10 mA, 120 kV) was performed to establish a protocol for all other scans. CT scans were acquired with a minimum slice thickness of 0.625 mm, pitch 1.375:1) and the highest possible tube current for these settings (320 mA @ 120 keV). PET emission events were collected in 3D scanning mode (septa out) over 60 min. Images were corrected for the decay of 68Ga and random events and reconstructed using the manufacturer’s 3D OSEM algorithm to 47 slices (display FOV = 6.4 cm, 128 × 128 matrix, resulting pixel size = 0.5 mm), once for each mouse separately in the center of the reconstruction cylinder. The in vivo images are presented as fused images of PET maximum intensity projection (MIP) and CT.

Data analysis

Statistical analysis was performed by unpaired two-tailed t test using GraphPad Prism 7 software (GraphPad Software Inc.). P values of < 0.05 were considered significant.


(Radio)metallated peptide conjugates, stability, and lipophilicity

All (metallated) conjugates were used with > 96% purity. The analytical data are reported in Table 1. The radiochemical yield of the 68Ga-preparations (non-isolated, estimated by radio-HPLC) was ≥ 98%, with a radiochemical purity ≥ 95% and an apparent molar activity of 50 MBq/nmol. [68Ga]Ga-DOTA-ST8950 was stable after 1 h at a room temperature (radiochemical purity remained ≥ 97%).

Table 1 Analytical data of the DOTA conjugates and of their corresponding natGa-complexes

[67Ga]Ga-DOTA-ST8950 was more lipophilic (log D = − 1.0 ± 0.1) than [67Ga]Ga-DOTA-NOC (log D = − 1.6 ± 0.1), while [67Ga]Ga-DOTA-TATE showed the highest hydrophilicity with a log D = − 3.0 ± 0.1.

Affinity studies

The results are summarized in Table 2. Values regarding SS-14, ST8950, octreotide, and pasireotide have been published in our recent study [25], but were measured head-to-head with all natGa-metallated compounds presented here. The IC50 of the natural SS-14 is in sub-nanomolar level for both receptor subtypes, while the IC50 of ST8950 correlates with the results reported by Moore et al. [24]. Conjugation of the chelate natGa-DOTA to ST8950 did not alter its binding affinity to SST2 (IC50 (95% CI): 0.32 (0.20–0.50) nM for natGa-DOTA-ST8950 vs 0.28 (0.19–0.42) nM for ST8950), but reduced by more than a factor of 2 its affinity to SST5 (IC50: 1.9 (1.1–3.1) vs 0.77 (0.48–1.2) nM, respectively). In comparison to natGa-DOTA-TATE, natGa-DOTA-ST8950 exhibited a lower affinity to SST2 (IC50: 0.15 (0.11–0.19) vs 0.32 (0.20–0.50) nM, respectively), but natGa-DOTA-TATE was unable to bind to SST5. Compared with natGa-DOTA-NOC, natGa-DOTA-ST8950 exhibited higher affinity for SST2 and SST5 (IC50: 0.70 (0.50–0.96) vs 0.32 (0.20–0.50) nM and 3.4 (1.8–6.2) vs 1.9 (1.1–3.1) nM, respectively [25]). Surprisingly, the de-iodinated analog natGa-DOTA-ST8951 demonstrated diminished affinities for SST2 and SST5, compared to natGa-DOTA-ST8950 and the reference compounds.

Table 2 Affinity toward SST2 and SST5 of all four natGa-DOTA-conjugates compared to reference somatostatin analogs

Functional assays

The results are summarized in Table 3. The EC50 values of SS-14, ST8950, octreotide, and pasireotide were published in our recent study [25], while all natGa-DOTA-conjugates are presented here. ST8950 was found to be a highly potent agonist of SST2 (EC50 (95% CI) = 0.29 (0.12–0.67) nM (similar to natural SS-14) [25]), but with a lower potency toward SST5 (EC50 = 8.5 (3.7–19) nM). However, ST8950 exhibited an intermediate agonistic potency on SST5 between pasireotide and octreotide, the latter being almost inactive on SST5. Introduction of the chelate natGa-DOTA reduces the agonistic potency for SST2 by a factor of 1.6 (EC50 = 0.46 (0.23–0.92) nM for natGa-DOTA-ST8950 vs 0.29 (0.12-0.67) nM for ST8950), and similar to (by a factor of 1.9) the agonistic potency for SST5 (EC50 = 16 (6.7–36) vs 8.5 (3.7–19) nM, respectively). Regarding the de-iodinated analog natGa-DOTA-ST8951, it loses massively its agonistic potency compared with natGa-DOTA-ST8950 and the reference compounds, similar to the observation at the binding affinity studies.

Table 3 Agonistic potency toward SST2 and SST5 of all four natGa-DOTA-conjugates compared to reference somatostatin analogs

In vitro characterization

[67Ga]Ga-DOTA-ST8950, [67Ga]Ga-DOTA-TATE, and [67Ga]Ga-DOTA-NOC showed specific and time-dependent cellular uptake on HEK-SST2 cells. The results are reported in Fig. 2. [67Ga]Ga-DOTA-ST8950 showed a similar (statistically not significantly different) internalization as [67Ga]Ga-DOTA-NOC (12.4 ± 1.6% vs 16.6 ± 2.2%, p = 0.0586, at 4 h), but statistically significantly lower than [67Ga]Ga-DOTA-TATE (12.4 ± 1.6% vs 24.2 ± 5.3%, p = 0.0216). The percentage of the surface-bound fraction was very low (~ 1%) in all cases, demonstrating that all surface-bound fraction is rapidly internalized inside the cells. [67Ga]Ga-DOTA-ST8951 had essentially no internalization on HEK-SST2, compared with the other radio-conjugates (1.1 ± 0.1%, at 4 h). None of the radio-conjugates had substantial internalization on HEK-SST5 cells ([67Ga]Ga-DOTA-ST8950: 1.2 ± 0.2%, [67Ga]Ga-DOTA-NOC 0.5 ± 0.1%, and [67Ga]Ga-DOTA-ST8951 < 0.5%, at 4 h). The internalization of [67Ga]Ga-DOTA-TATE was not evaluated on HEK-SST5, and it has no affinity to SST5.

Fig. 2

Internalization of the 67Ga-labeled conjugates in HEK-SST2 cells over time, expressed as % (mean ± SD) of applied activity in the cells and normalized per million cells. All values refer to specific internalization after subtracting the non-specific (measured in the presence of 1000-fold excess of SS-14) from the total internalized fraction, at each time point

The results of the cellular retention of [67Ga]Ga-DOTA-ST8950, [67Ga]Ga-DOTA-TATE, and [67Ga]Ga-DOTA-NOC in HEK-SST2 are presented in Fig. 3. The efflux was in the same range for the three 67Ga-labeled conjugates. [67Ga]Ga-DOTA-NOC showed the lower efflux (34% after 4 h at 37 °C), while [67Ga]Ga-DOTA-ST8950 the highest (49% after 4 h at 37 °C); however, there was no statistically significant difference between [67Ga]Ga-DOTA-ST8950 and [67Ga]Ga-DOTA-NOC (p = 0.0574) or [67Ga]Ga-DOTA-TATE (p = 0.1308).

Fig. 3

Cellular retention of the 67Ga-labeled conjugates in HEK-SST2 cells over time, expressed as % (mean ± SD) of the internalized activity

Biodistribution studies of [68Ga]Ga-DOTA-ST8950 and [68Ga]Ga-DOTA-NOC

The biodistribution results are presented in Table 4. [68Ga]Ga-DOTA-ST8950 showed high accumulation in both SST2- and SST5-expressing tumors and in SST-positive tissues, such as the pancreas, stomach, and pituitary. In general, [68Ga]Ga-DOTA-ST8950 showed relatively long circulation in the blood, as indicated by the blood values at 1 h and 2 h p.i. (1.9 ± 0.6 and 0.8 ± 0.2 %IA/g, respectively). The accumulation in the kidneys (14 ± 4 %IA/g at 1 h p.i., remaining at the same level after 2 h) indicates urinary excretion and renal retention. The liver uptake of [68Ga]Ga-DOTA-ST8950 is rather high (6.4 ± 1.9 %IA/g), compared to [68Ga]Ga-DOTA-NOC (2.3 ± 0.7 %IA/g). The significantly low tumor uptake of [68Ga]Ga-DOTA-ST8950 in HEK-SST-negative xenografts (1.4 ± 0.5 %IA/g), versus 26 ± 8 %IA/g in HEK-SST2 tumors and 15 ± 6 %IA/g in HEK-SST5 tumors at 1 h p.i. confirms the receptor-mediated uptake (specificity) of [68Ga]Ga-DOTA-ST8950.

Table 4 Biodistribution results of [68Ga[Ga-DOTA-ST8950 at 1 and 2 h p.i. and [68Ga]Ga-DOTA-NOC at 1 h p.i

The biodistribution of [68Ga]Ga-DOTA-NOC was similar to [68Ga]Ga-DOTA-ST8950 at 1 h p.i., with high and specific accumulation in SST2 and SST5 tumors and in SST-positive tissues. However, [68Ga]Ga-DOTA-ST8950 showed slightly higher blood values and higher kidney and liver uptake, compared to [68Ga]Ga-DOTA-NOC, which had in turn higher accumulation in the SST-positive organs, such as the pancreas and stomach.

PET/CT imaging of [68Ga]Ga-DOTA-ST8950 and [68Ga]Ga-DOTA-NOC

PET/CT images of [68Ga]Ga-DOTA-ST8950 and [68Ga]Ga-DOTA-NOC at 1 h p.i. revealed high image contrast with clear visualization of both SST2 and SST5 tumors (Fig. 4). The highest tracer uptake is visible in the tumors and in the kidneys. Accumulation of [68Ga]Ga-DOTA-ST8950 is also detected in the liver, in agreement with the biodistribution data, though lower than in the kidneys and the tumors.

Fig. 4

Maximum intensity projection (MIP) PET/CT images of [68Ga]Ga-DOTA-ST8950 and [68Ga]Ga-DOTA-NOC (100 μL/100 pmol/5 MBq, apparent molar activity of 50 MBq/nmol) in a dual SST2- and SST5-expressing tumor mouse model, 1 h after the injection of the radiotracer (SUV: standard uptake value)


Various expression and co-expression patterns have been described for the 5 somatostatin receptor subtypes (SST1-5), depending on the tumor type and origin [5, 6, 28]. Interestingly, tumor area lacking expression of a given subtype may be populated by another one [4, 5, 8]. Hence, somatostatin analogs with affinity to more than one receptor subtypes are of great interest as they address receptor subtype co-expression and heterogeneous expression patterns.

Two independent studies comparing the diagnostic efficacy [68Ga]Ga-DOTA-NOC, a somatostatin analog with a high affinity for SST2 and SST5 and a lower affinity for SST3, with the SST2-selective [68Ga]Ga-DOTA-TATE in NET patients, provided controversial results on the clinical outcome of multi-receptor subtype targeting. Kabasakal et al. [29], concluded that even though the images have comparable diagnostic accuracy, [68Ga]Ga-DOTA-TATE detected more lesions. Contrary to this, Wild et al. [30] reported that [68Ga]Ga-DOTA-NOC detected significantly more lesions than [68Ga]Ga-DOTA-TATE (sensitivity: 93.5 vs 85.5%) and it changed the clinical management in 17% of the studied patients. Recently, Lamarca et al. [31] confirmed the role of [68Ga]Ga-DOTA-NOC PET imaging for the optimization of the clinical management in lung carcinoid patients. Overall, the clinical data support that multi-receptor subtype targeting is relevant for improving the diagnostic accuracy and sensitivity of PET imaging of SST-expressing tumors. Therefore, effort needs to be made for developing new radiotracers in this direction.

With the aim to develop 68Ga-tracers for combined SST2 and SST5 targeting, we focused on the series of compounds reported by Moore et al. [24], who used synthetic amino acids, among them iodo-substituted ones, to improve binding affinities. There are several cases in the literature where (radio)iodination of somatostatin analogs either did not affect or improve the binding affinity and/or potency [8, 32, 33]. In the series of Moore et al., iodination at position 3 (3-iodo-Tyr3, peptide #6 in reference [24]) showed improved affinity to SST5 by an order of magnitude, followed unluckily, by a 4-fold reduction in the affinity to SST2. Similar observations on SST5 were reported by Schotellius et al. [33]. Iodination at position 3 of DOTA-TATE (DOTA-3-iodo-Tyr3-octreotate: HA-TATE) enhanced the affinity of natGa-DOTA-HA-TATE to SST5, compared with natGa-DOTA-TATE (IC50 = 102 ± 65 vs > 1000 nM, respectively), but did not affect the affinity to SST2, contrary to Moore et al. Taken together, the two studies indicate that iodo-substitution of Tyr3 on the octreotide motif improves affinity to SST5.

Modification of ST8950 at the N-terminal by coupling of DOTA and complexation with Ga3+ does not affect the affinity for SST2, while reduces the affinity for SST5 by a factor of approx. 2. Nevertheless, natGa-DOTA-ST8950 retains its affinity in sub- (SST2) or one-digit (SST5) nanomolar range. It worth mentioning that the determined IC50 of ST8950 is in very good agreement with the results reported by Moore et al. [24] (0.6 for SST2 and 0.7 nM for SST5). Conversely, the de-iodinated analog ST8951 (IC50 = 1.6 nM for SST2 and 14 nM for SST5 in reference [24]) after the coupling of the chelate natGa-DOTA losses massively its affinity for both, SST2 and SST5 (IC50 = 7.5 and 24 nM, respectively). The effect is more prominent in the SST2, for which ST8951 shows higher selectively. In addition, we evaluated to which extend ST8950 and ST8951 retain their agonistic potencies after Ga-DOTA conjugation, in light of examples in the literature indicating that modifications like DOTA conjugation can change the function of a somatostatin analog from an antagonist to an agonist [34]. The agonistic potencies of natGa-DOTA-ST8950 and natGa-DOTA-ST8951 followed an identical trend as their affinities to both SST2 and for SST5.

[67Ga]Ga-DOTA-ST8950 had similar internalization rate as [67Ga]Ga-DOTA-NOC, but significantly lower than [67Ga]Ga-DOTA-TATE in HEK-SST2 cells. All three radiotracers had very low surface-bound fraction, confirming their agonistic nature that leads to instant internalization of the radiotracer upon binding to the receptor on the cell surface. Four hours after internalization, half of the [67Ga]Ga-DOTA-ST8950 still remains inside the cells. There was no statistically significant difference in the efflux rate between [67Ga]Ga-DOTA-ST8950 and [67Ga]Ga-DOTA-NOC or [67Ga]Ga-DOTA-TATE. [67Ga]Ga-DOTA-ST8951 showed essentially no internalization in HEK-SST2. The inability of [67Ga]Ga-DOTA-ST8951 to bind and internalize on SST2-expressing cells, together with its loss of affinity for SST2 and SST5, led us to exclude [67/68Ga]Ga-DOTA-ST8951 from further studies.

In vitro experiments on HEK-SST5 did not show any internalization (neither cell surface-bound) for any of the tested radiotracers. This may be due to the particular cellular distribution and trafficking of SST5 [35, 36] and not due to the radiotracers. This phenomenon was also observed by others using somatostatin analogs with a high affinity for SST5 [10, 35]. Cescato et al. [35] showed that SST5 internalization can be induced by natural somatostatin peptides but not by synthetic high-affinity SST5 agonists. Indeed, Maina et al showed in vitro internalization on HEK-SST5 of an 111In-labeled modified analog of the natural SS-28 [22], even though very low (approx. 2.5% after 1 h at 37 °C) and unusually high (50%) nonspecific portion. Our data are in line with the published findings. Importantly, the lack of in vitro internalization in SST5-expressing cells does not exclude the accumulation of the radiotracer in SST5-expressing tumors in vivo. Our in vivo data prove this.

The in vivo distribution of [68Ga]Ga-DOTA-ST8950 is representative of radiolabeled somatostatin analogs, regarding the accumulation in SST-positive tissues, such as the stomach, the pancreas, and the pituitary. [68Ga]Ga-DOTA-ST8950 showed high uptake in both SST2- and SST5-expressing tumors, similar to [68Ga]Ga-DOTA-NOC (p = 0.4630 for SST2 and p = 0.3282 for SST5), proven to be receptor subtype mediated by the 90% reduction found on the SST-negative tumor. The kidneys were the second tissue after the tumors accumulating radioactivity, which was expected due to the renal excretion of this class of radiotracers. Unluckily, the lipophilic character of [68Ga]Ga-DOTA-ST8950 was reflected on its biodistribution profile, with rather high blood and liver values. Nevertheless, when we compared with the 68Ga-labeled pasireotide which also targets SST2 and SST5 (referred as 68Ga-DOTA-SOM230 in [15, 16]) in the same animal model, [68Ga]Ga-DOTA-ST8950 has advantages in terms of lower blood values (1.9 ± 0.6 vs 4.1 ± 0.9 %IA/g at 1 h p.i.) and liver uptake (6.4 ± 1.9 vs 12.9 ± 2.2 %IA/g at 1 h p.i.). Liu et al. confirmed similarly high blood values and even higher liver uptake for the 68Ga-labeled pasireotide (referred as 68Ga-DOTA-PA1 in [17]). However, [68Ga]Ga-DOTA-ST8950 has certain limitations when compared with the clinically used [68Ga]Ga-DOTA-NOC and [68Ga]Ga-DOTA-TATE. The blood and liver values of [68Ga]Ga-DOTA-ST8950 are higher than [68Ga]Ga-DOTA-NOC (Table 4, p = 0.0141 and p = 0.0005, respectively) and much higher when compared with our previous data on [68Ga]Ga-DOTA-TATE [37] (blood: 1.9 ± 0.6 vs 0.4 ± 0.0 %IA/g and liver 6.4 ± 1.9 vs 0.4 ± 0.2 %IA/g, respectively). On the other hand, [68Ga]Ga-DOTA-NOC demonstrated higher uptake in the SST-positive stomach and pancreas, while [68Ga]Ga-DOTA-TATE cannot be used for imaging SST5-expressing tumors as it is unable to bind to this receptor subtype.

PET/CT imaging is reflecting the biodistribution data, with clear visualization of SST2- and SST5-expressing tumors and high image contrast for [68Ga]Ga-DOTA-ST8950 and for [68Ga]Ga-DOTA-NOC. The higher kidney uptake of [68Ga]Ga-DOTA-ST8950, compared with [68Ga]Ga-DOTA-NOC (p = 0.0399), is of no concern for a diagnostic tracer. However, the accumulation of [68Ga]Ga-DOTA-ST8950 in the liver is a drawback. Especially when recognizing that the liver is the first site of metastasis of NETs, and therefore, low background activity is needed for a good image contrast and diagnostic accuracy. Two approaches are considered to circumvent this problem: (a) a chemical approach that involves modification of the structure by introducing hydrophilic spacers and/or amino acids and (b) a pharmacological approach by enhancing the tumor uptake via epigenetic receptor upregulation [38], improving tumor-to-liver ratio. The second approach is mainly considered for the therapeutic counterpart [177Lu]Lu-DOTA-ST8950.


The preclinical evaluation of the 2-iodo-substituted somatostatin analog [68Ga]Ga-DOTA-ST8950 reveals its potential as PET tracer for in vivo imaging of SST2- and SST5-expressing tumors, which may be of interest for gastroenteropancreatic neuroendocrine tumors, pituitary tumors, and gastric cancers. Its in vivo uptake in the tumors compares favorably with the uptake of the clinically used [68Ga]Ga-DOTA-NOC, but its high accumulation in the liver remains a challenge for clinical translation. While iodination in positions 1 and 3 seemed not to be a prerequisite for a good binding affinity of ST8950 and of the de-iodinated ST8951 to SST2 and SST5, this is proven to be essential in their [68Ga]Ga-DOTA-chelated versions. [68Ga]Ga-DOTA-ST8951 lost its affinity and potency for both subtypes, and it is disqualified for usage as a PET tracer.

Availability of data and materials

The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.



Computed tomography


Dulbecco’s modified Eagle’s medium


1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid


Diethylenetriaminepentaacetic acid


Electrospray ionization mass spectroscopy


Fetal bovine serum


Neuroendocrine tumor


Phosphate-buffered saline


Positron emission tomography




Reverse phase high-performance liquid chromatography


Somatostatin receptor






  1. 1.

    Reubi JC, Schar JC, Waser B, Wenger S, Heppeler A, Schmitt JS, et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med. 2000;27:273–82.

    CAS  PubMed  Google Scholar 

  2. 2.

    Asnacios A, Courbon F, Rochaix P, Bauvin E, Cances-Lauwers V, Susini C, et al. Indium-111-pentetreotide scintigraphy and somatostatin receptor subtype 2 expression: new prognostic factors for malignant well-differentiated endocrine tumors. J Clin Oncol. 2008;26:963–70.

    PubMed  Google Scholar 

  3. 3.

    Buscail L, Esteve JP, Saint-Laurent N, Bertrand V, Reisine T, O'Carroll AM, et al. Inhibition of cell proliferation by the somatostatin analogue RC-160 is mediated by somatostatin receptor subtypes SSTR2 and SSTR5 through different mechanisms. Proc Natl Acad Sci U S A. 1995;92:1580–4.

    CAS  PubMed  PubMed Central  Google Scholar 

  4. 4.

    Kulaksiz H, Eissele R, Rossler D, Schulz S, Hollt V, Cetin Y, et al. Identification of somatostatin receptor subtypes 1, 2A, 3, and 5 in neuroendocrine tumours with subtype specific antibodies. Gut. 2002;50:52–60.

    CAS  PubMed  PubMed Central  Google Scholar 

  5. 5.

    Papotti M, Bongiovanni M, Volante M, Allia E, Landolfi S, Helboe L, et al. Expression of somatostatin receptor types 1-5 in 81 cases of gastrointestinal and pancreatic endocrine tumors. A correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysis. Virchows Arch. 2002;440:461–75.

    CAS  PubMed  Google Scholar 

  6. 6.

    Reubi JC, Waser B. Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging. 2003;30:781–93.

    CAS  PubMed  Google Scholar 

  7. 7.

    Forssell-Aronsson EB, Nilsson O, Bejegard SA, Kolby L, Bernhardt P, Molne J, et al. 111In-DTPA-D-Phe1-octreotide binding and somatostatin receptor subtypes in thyroid tumors. J Nucl Med. 2000;41:636–42.

    CAS  PubMed  Google Scholar 

  8. 8.

    Rivier JE, Hoeger C, Erchegyi J, Gulyas J, DeBoard R, Craig AG, et al. Potent somatostatin undecapeptide agonists selective for somatostatin receptor 1 (sst1). J Med Chem. 2001;44:2238–46.

    CAS  PubMed  Google Scholar 

  9. 9.

    Traub T, Petkov V, Ofluoglu S, Pangerl T, Raderer M, Fueger BJ, et al. 111In-DOTA-lanreotide scintigraphy in patients with tumors of the lung. J Nucl Med. 2001;42:1309–15.

    CAS  PubMed  Google Scholar 

  10. 10.

    Antunes P, Ginj M, Zhang H, Waser B, Baum RP, Reubi JC, et al. Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals? Eur J Nucl Med Mol Imaging. 2007;34:982–93.

    CAS  PubMed  Google Scholar 

  11. 11.

    Wild D, Schmitt JS, Ginj M, Macke HR, Bernard BF, Krenning E, et al. DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals. Eur J Nucl Med Mol Imaging. 2003;30:1338–47.

    CAS  PubMed  Google Scholar 

  12. 12.

    Wild D, Macke HR, Waser B, Reubi JC, Ginj M, Rasch H, et al. 68Ga-DOTANOC: a first compound for PET imaging with high affinity for somatostatin receptor subtypes 2 and 5. Eur J Nucl Med Mol Imaging. 2005;32:724.

    PubMed  Google Scholar 

  13. 13.

    Lewis I, Bauer W, Albert R, Chandramouli N, Pless J, Weckbecker G, et al. A novel somatostatin mimic with broad somatotropin release inhibitory factor receptor binding and superior therapeutic potential. J Med Chem. 2003;46:2334–44.

    CAS  PubMed  Google Scholar 

  14. 14.

    Schmid HA. Pasireotide (SOM230): development, mechanism of action and potential applications. Mol Cell Endocrinol. 2008;286:69–74.

    CAS  PubMed  Google Scholar 

  15. 15.

    Fani M, Braun F, Mann A, Kliewer A, Kaufmann J, Weber WA, et al. Development of the 68Ga-labeled pan-somatostatin analog SOM230 (SOMscan). Abstract. J Nucl Med. 2012;53:1686.

    Google Scholar 

  16. 16.

    Fani M, Gourni E, Braun F, Mann A, Kliewer A, Kaufmann J, et al. Development and Preclinical Evaluation of the New Pan-Somatostatin PET Imaging Probe 68Ga-DOTA-SOM230 (SOMscan®). Abstract. NANETS. 2012;2012:C16.

    Google Scholar 

  17. 17.

    Liu F, Liu T, Xu X, Guo X, Li N, Xiong C, et al. Design, synthesis, and biological evaluation of (68)Ga-DOTA-PA1 for lung cancer: a novel PET tracer for multiple somatostatin receptor imaging. Mol Pharm. 2018;15:619–28.

    CAS  PubMed  Google Scholar 

  18. 18.

    Ginj M, Chen J, Walter MA, Eltschinger V, Reubi JC, Maecke HR. Preclinical evaluation of new and highly potent analogues of octreotide for predictive imaging and targeted radiotherapy. Clin Cancer Res. 2005;11:1136–45.

    CAS  PubMed  Google Scholar 

  19. 19.

    Ginj M, Zhang H, Eisenwiener KP, Wild D, Schulz S, Rink H, et al. New pansomatostatin ligands and their chelated versions: affinity profile, agonist activity, internalization, and tumor targeting. Clin Cancer Res. 2008;14:2019–27.

    CAS  PubMed  Google Scholar 

  20. 20.

    Tatsi A, Maina T, Cescato R, Waser B, Krenning EP, de Jong M, et al. [111In-DOTA]Somatostatin-14 analogs as potential pansomatostatin-like radiotracers - first results of a preclinical study. EJNMMI Res. 2012;2:25.

    PubMed  PubMed Central  Google Scholar 

  21. 21.

    Tatsi A, Maina T, Cescato R, Waser B, Krenning EP, de Jong M, et al. [DOTA]Somatostatin-14 analogs and their (111)In-radioligands: effects of decreasing ring-size on sst1-5 profile, stability and tumor targeting. Eur J Med Chem. 2014;73:30–7.

    CAS  PubMed  Google Scholar 

  22. 22.

    Maina T, Cescato R, Waser B, Tatsi A, Kaloudi A, Krenning EP, et al. [111In-DOTA]LTT-SS28, a first pansomatostatin radioligand for in vivo targeting of somatostatin receptor-positive tumors. J Med Chem. 2014;57:6564–71.

    CAS  PubMed  Google Scholar 

  23. 23.

    Cai RZ, Szoke B, Lu R, Fu D, Redding TW, Schally AV. Synthesis and biological activity of highly potent octapeptide analogs of somatostatin. Proc Natl Acad Sci U S A. 1986;83:1896–900.

    CAS  PubMed  PubMed Central  Google Scholar 

  24. 24.

    Moore SB, van der Hoek J, de Capua A, van Koetsveld PM, Hofland LJ, Lamberts SW, et al. Discovery of iodinated somatostatin analogues selective for hsst2 and hsst5 with excellent inhibition of growth hormone and prolactin release from rat pituitary cells. J Med Chem. 2005;48:6643–52.

    CAS  PubMed  Google Scholar 

  25. 25.

    Streuli J, Harris AG, Cottiny C, Allagnat F, Daly AF, Grouzmann E, et al. Cellular effects of AP102, a somatostatin analog with balanced affinities for the hSSTR2 and hSSTR5 receptors. Neuropeptides. 2018;68:84–9.

    CAS  PubMed  Google Scholar 

  26. 26.

    Tarasco E, Seebeck P, Pfundstein S, Daly AF, Eugster PJ, Harris AG, et al. Effect of AP102, a subtype 2 and 5 specific somatostatin analog, on glucose metabolism in rats. Endocrine. 2017;58:124–33.

    CAS  PubMed  Google Scholar 

  27. 27.

    Fani M, Del Pozzo L, Abiraj K, Mansi R, Tamma ML, Cescato R, et al. PET of somatostatin receptor-positive tumors using 64Cu- and 68Ga-somatostatin antagonists: the chelate makes the difference. J Nucl Med. 2011;52:1110–8.

    CAS  PubMed  Google Scholar 

  28. 28.

    Taboada GF, Luque RM, Bastos W, Guimaraes RF, Marcondes JB, Chimelli LM, et al. Quantitative analysis of somatostatin receptor subtype (SSTR1-5) gene expression levels in somatotropinomas and non-functioning pituitary adenomas. Eur J Endocrinol. 2007;156:65–74.

    CAS  PubMed  Google Scholar 

  29. 29.

    Kabasakal L, Demirci E, Ocak M, Decristoforo C, Araman A, Ozsoy Y, et al. Comparison of (6)(8)Ga-DOTATATE and (6)(8)Ga-DOTANOC PET/CT imaging in the same patient group with neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2012;39:1271–7.

    PubMed  Google Scholar 

  30. 30.

    Wild D, Bomanji JB, Benkert P, Maecke H, Ell PJ, Reubi JC, et al. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors. J Nucl Med. 2013;54:364–72.

    CAS  PubMed  Google Scholar 

  31. 31.

    Lamarca A, Pritchard DM, Westwood T, Papaxoinis G, Nonaka D, Vinjamuri S, et al. 68Gallium DOTANOC-PET imaging in lung carcinoids: impact on patients' management. Neuroendocrinology. 2018;106:128–38.

    CAS  PubMed  Google Scholar 

  32. 32.

    Woltering EA, O'Dorisio MS, Murphy WA, Chen F, Drouant GJ, Espenan GD, et al. Synthesis and characterization of multiply-tyrosinated, multiply-iodinated somatostatin analogs. J Pept Res. 1999;53:201–13.

    CAS  PubMed  Google Scholar 

  33. 33.

    Schottelius M, Simecek J, Hoffmann F, Willibald M, Schwaiger M, Wester HJ. Twins in spirit - episode I: comparative preclinical evaluation of [(68)Ga]DOTATATE and [(68)Ga]HA-DOTATATE. EJNMMI Res. 2015;5:22.

    PubMed  PubMed Central  Google Scholar 

  34. 34.

    Reubi JC, Erchegyi J, Cescato R, Waser B, Rivier JE. Switch from antagonist to agonist after addition of a DOTA chelator to a somatostatin analog. Eur J Nucl Med Mol Imaging. 2010;37:1551–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  35. 35.

    Cescato R, Schulz S, Waser B, Eltschinger V, Rivier JE, Wester HJ, et al. Internalization of sst2, sst3, and sst5 receptors: effects of somatostatin agonists and antagonists. J Nucl Med. 2006;47:502–11.

    CAS  PubMed  Google Scholar 

  36. 36.

    Stroh T, Jackson AC, Sarret P, Dal Farra C, Vincent JP, Kreienkamp HJ, et al. Intracellular dynamics of sst5 receptors in transfected COS-7 cells: maintenance of cell surface receptors during ligand-induced endocytosis. Endocrinology. 2000;141:354–65.

    CAS  PubMed  Google Scholar 

  37. 37.

    Fani M, Braun F, Waser B, Beetschen K, Cescato R, Erchegyi J, et al. Unexpected sensitivity of sst2 antagonists to N-terminal radiometal modifications. J Nucl Med. 2012;53:1481–9.

    CAS  PubMed  Google Scholar 

  38. 38.

    Taelman VF, Radojewski P, Marincek N, Ben-Shlomo A, Grotzky A, Olariu CI, et al. Upregulation of key molecules for targeted imaging and therapy. J Nucl Med. 2016;57:1805–10.

    PubMed  Google Scholar 

Download references


We acknowledge Sandra Zanger and Rudolf von Wartburg for their assistance with the animal experiments.


The study was financially supported by the Swiss Confederation Commission for Technology and Innovation (CTI) Project Nrs. 16403.2 PFLS-LS and 18282.2 PFLS-LS.

Author information




RM and LDP: chemical synthesis, purification, analytical data, and radiochemistry. RM: radioligand based in vitro assays and original draft writing. EG and KA: biological in vitro assays. GN: analysis and reconstruction of the PET/CT images and manuscript editing. MF: study design, supervision, and manuscript editing. All the authors have made a substantial intellectual contribution and read and approved the final manuscript.

Corresponding author

Correspondence to Melpomeni Fani.

Ethics declarations

Ethics approval and consent to participate

Animal studies were approved by the Swiss Federal Food Safety and Veterinary Office (approval no. 2799).

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Mansi, R., Abid, K., Nicolas, G.P. et al. A new 68Ga-labeled somatostatin analog containing two iodo-amino acids for dual somatostatin receptor subtype 2 and 5 targeting. EJNMMI Res 10, 90 (2020).

Download citation


  • Somatostatin receptor subtypes
  • Somatostatin agonists
  • SST2
  • SST5
  • 68Ga
  • PET
  • Neuroendocrine tumors
  • Iodo-amino acids